All In Biotech

Drug Trial Radar · NCT00156897

Efficacy and Safety of ATL-962 in Obese Diabetics

Multicentre Double Blind Placebo Controlled Parallel Group Dose Ranging Study of ATL-962 to Assess Weight Loss, Safety and Tolerability in Obese Patients With Type II Diabetes Being Treated With Metformin, in Comparison With Orlistat

Last checked: Nov 20, 2026Latest source record: Aug 29, 2006 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

600

Actual

Start

Dec 2004

Primary completion

Not stated

Study completion Oct 2005

Sponsor

Lead sponsor
AlizymeIndustry
Sponsor type
Industry
First posted
Sep 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate whether ATL-962 induces weight loss in diabetic patients and whether its safety and tolerability profile is superior to that of orlistat in such patients

Conditions

  • Non-Insulin-Dependent Diabetes Mellitus
  • Obesity

Interventions

  • ATL-962Drug

  • OrlistatDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute weight loss compared to baseline

Locations

37 sites in 5 countries. Site status is shown where the registry gives one.

  • Aalborg Sygehus Nord

    Aalborg, Denmark

  • Aarhus University Hospital

    Aarhus, Denmark

  • Bispebjerg Hospital

    Copenhagen, Denmark

  • Gentofte Hospital

    Hellerup, Denmark

  • Hvidovre Hospital

    Hvidovre, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Lääkärikeskus Minerva

    Eura, Finland

  • Obesity Research Unit

    Helsinki, Finland

  • Suomen Terveystalo

    Jyväskylä, Finland

  • Oy Foodfiles Limited

    Kuopio, Finland

  • Oulun Diakonissalaitos

    Oulu, Finland

  • University of Oulu

    Oulu, Finland

  • Turku University Hospital

    Turku, Finland

  • Allevon

    Den Bosch Ziekenhuis, Netherlands

  • Allevon

    DN de Bilt, Netherlands

  • Zeikenhuisgroep Twente

    Hengelo, Netherlands

  • Nederlandse Obesitas Klinik

    Hilversum, Netherlands

  • Sint Franciscus Gasthuis

    Rotterdam, Netherlands

  • Sahlgrenska University Hospital

    Gothenburg, Sweden

  • Linkoping University Hospital

    Linköping, Sweden

  • Karolinsaka University Hospital

    Stockholm, Sweden

  • Norrlands Universitetssjukhus

    Umeå, Sweden

  • Samariterhemmets Sjukhus

    Uppsala, Sweden

  • Aberdeen Royal Infirmary

    Aberdeen, United Kingdom

  • Royal United Hospital

    Bath, United Kingdom

  • Clinical Research Centre Edgbaston

    Birmingham, United Kingdom

  • Walsgrave Hospital

    Coventry, United Kingdom

  • Glasgow Royal Infirmary

    Glasgow, United Kingdom

  • Clinical Research Centre, Crosby

    Liverpool, United Kingdom

  • Liverpool University Hospital

    Liverpool, United Kingdom

  • Queen Mary's School of Medicine & Dentistry

    London, United Kingdom

  • Hammersmith Hospital

    London, United Kingdom

  • Luton & Dunstable Hospital

    Luton, United Kingdom

  • Clinical Research Centre

    Manchester, United Kingdom

  • James Cook University Hospital

    Middlesbrough, United Kingdom

  • Royal Shrewsbury Hospital

    Shrewsbury, United Kingdom

  • Clinical Research Centre

    Wigan, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.